A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback